secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2025-07-25T23:59:59+00:00
Accession:  0001999371-25-009884
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix reports preliminary Q2 net operating loss of $26.3M, cash $125.3M, runway to Q3 2026
--------------------------------------------------------------------------------

- Net operating loss of $26.3M in Q2 2025, improved from $78.8M in Q2 2024.
- Cash and equivalents $125.3M at June 30; additional $50.6M raised in Q3 2025 equity offerings.
- Net cash used in ops $16.3M ($9.9M in Q2 2024); capex $1.1M (nil prior year).
- Revenue from marketed products $2.0M, down from $2.2M YoY.
- Company expects runway into Q3 2026; shares outstanding 8.7M as of July 25.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125009884/0001999371-25-009884-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125009884/tnxp-8k_072525.htm
  HTML page:      https://secwatch.observer/filing/0001999371-25-009884

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer